Valuation: Lipocine Inc.

Market Cap 18.14M 15.97M 15.13M 13.66M 25.75M 1.74B 26.08M 181M 69.67M 889M 68.11M 66.62M 2.85B P/E 2026 *
-1.42x
P/E 2027 * -1.64x
Enterprise Value 18.14M 15.97M 15.13M 13.66M 25.75M 1.74B 26.08M 181M 69.67M 889M 68.11M 66.62M 2.85B EV / Sales 2026 *
28.7x
EV / Sales 2027 * 24.3x
Free-Float
95.49%
Yield 2026 *
-
Yield 2027 * -
1 day+1.85%
1 week+3.77%
1 month-1.79%
3 months-14.06%
6 months-72.47%
Current year-72.60%
1 week 2.06
Extreme 2.06
2.25
1 month 2.06
Extreme 2.06
2.5
Current year 1.81
Extreme 1.81
12.37
1 year 1.81
Extreme 1.81
12.37
3 years 1.81
Extreme 1.81
12.37
5 years 1.81
Extreme 1.81
32.13
10 years 1.81
Extreme 1.81
100.3
Manager TitleAgeSince
Chief Executive Officer 69 1996-12-31
Chief Tech/Sci/R&D Officer 56 2022-11-30
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 2014-01-07
Director/Board Member 58 2002-12-31
Chairman 73 2026-04-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Free

Director

2,000 0.0243%
6/3/26 Free

Director

1,764 0.0214%
6/3/26 Free

Chairman

1,764 0.0214%
Change 5-day change 1-year change 3-year change Capi.($)
+1.85%+3.77%-22.81%-26.17% 17.81M
+4.16%-0.36%+49.37%+94.17% 71.53B
-0.19%+1.32%+37.20%+83.85% 60.12B
-1.51%+2.39%+9.10%+35.15% 48.85B
-0.05%+0.37%+41.54%+36.65% 44.28B
+0.38%+7.61%+339.53%+641.55% 43.83B
+0.18%+0.26%+7.41%+103.45% 41.53B
-0.67%+0.17%+7.60%+46.37% 30.13B
+4.77%+6.16%+36.77%+22.78% 27.98B
-1.29%-3.55%-20.74%+352.04% 25.25B
Average +0.76%+1.44%+48.50%+138.98% 39.35B
Weighted average by Cap. +0.80%+1.37%+60.92%+148.54%

Financials

2026 *2027 *
Net sales 631K 556K 527K 475K 896K 60.53M 908K 6.3M 2.42M 30.94M 2.37M 2.32M 99.2M 745K 656K 622K 561K 1.06M 71.43M 1.07M 7.44M 2.86M 36.52M 2.8M 2.74M 117M
Net income -12.64M -11.13M -10.55M -9.52M -17.95M -1.21B -18.18M -126M -48.57M -620M -47.47M -46.44M -1.99B -16.22M -14.28M -13.53M -12.22M -23.02M -1.55B -23.32M -162M -62.3M -795M -60.9M -59.57M -2.55B
Net Debt - -
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
26-09-30 US$2.200 +1.85% 31,368
26-09-29 US$2.160 +3.35% 24,256
26-09-28 US$2.090 -0.48% 34,438
26-09-25 US$2.100 +0.48% 32,766
26-09-24 US$2.090 -1.42% 32,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.200USD
Average target price
5.000USD
Spread / Average Target
+127.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LPCN Stock